Clinical Trials (PDQ®) - National Cancer Institute

Page Options

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights

Study to Determine the Efficacy of Bendamustin in Patients With Recurrent Small Cell Lung Cancer (SCLC)

Basic Trial Information
Trial Description
     Summary
     Further Trial Information
     Eligibility Criteria
Trial Contact Information

Basic Trial Information

Phase
Type
Status
Age
Sponsor
Protocol IDs

Phase II

Treatment

Active

18 to 70

Other

Haema CBF SCLC UK/AS 02
NCT00168922

Trial Description

Summary

Determination of response rate Assessment of toxicity and determination of "time to progression"

Further Study Information

Phase II Study to determine the efficacy of Bendamustin(Ribomustin) in patients with recurrent small cell bronchial carcinoma after cytostatic polychemotherapy

Eligibility Criteria

Inclusion Criteria:

Patients with histological proven, curative non treatable small lung cell carcinoma

Recurrence >8 weeks, > 1 year after 1st line treatment with platin- and etoposide polychemotherapy, without brain metastases

Exclusion Criteria:

Brain metastases

WHO-PS 3 - 4

Trial Contact Information

Trial Lead Organizations/Sponsors

Charite University Hospital - Campus Virchow Klinikum

Ribosepharm GmbH

Ulrich Keilholz

Principal Investigator

Ulrich Keilholz, MD		Ph: +49-30-8445-3596
		Email: ulrich.keilholz@charite.de

Alexander Schmittel, MD		Ph: +49-30-8445-3090
		Email: alexander.schmittel@charite.de

Trial Sites

Germany

Berlin

Charite - Universitaetsmedizin Berlin - Campus Benjamin Franklin

Ulrich Keilholz, MD Ph: +49-30-8445-3596

Email: ulrich.keilholz@charite.de

Alexander Schmittel, MD Ph: +49-30-8445-3090

Email: alexander.schmittel@charite.de

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00168922
Information obtained from ClinicalTrials.gov on May 27, 2008

Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.